John Higuchi
Vermögen: 458 543 $ am 31.05.2026
Vermögen: 458 543 $ am 31.05.2026
John W.
Higuchi is the founder of Spriaso LLC.
Mr. Higuchi is an Independent Director at Lipocine, Inc. since 2003.
Mr. Higuchi was Chief Executive Officer at Aciont, Inc. from 2003 to 2022.
Mr. Higuchi completed graduate and MBAistration degrees at George Washington University and an undergraduate degree at Hope College.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
LIPOCINE INC 2.47% | 03.06.2026 | 203’797 ( 2.47% ) | 458 543 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| LIPOCINE INC. | Direktor/Vorstandsmitglied | 01.01.2003 |
Spriaso LLC
Spriaso LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Gründer | - |
| Unternehmen | Position | Ende |
|---|---|---|
Aciont, Inc.
Aciont, Inc. Medical DistributorsDistribution Services Engages in commercializing of localized, non-invasive, controlled and sustained release back of the eye therapeutics | Vorstandsvorsitzender | 01.01.2022 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 5 |
|---|---|
George Washington University
George Washington University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Hope College
Hope College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Lipocine, Inc.
Lipocine, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in research and development for the delivery of drugs | Health Technology |
Aciont, Inc.
Aciont, Inc. Medical DistributorsDistribution Services Engages in commercializing of localized, non-invasive, controlled and sustained release back of the eye therapeutics | Distribution Services |
Spriaso LLC
Spriaso LLC Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen